This Article Full Text Full Text (PDF) All Versions of this Article: 26/11/2439    most recent 01.ATV.0000243924.00970.cbv1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Moens, A. L. Articles by Kass, D. A. Search for Related Content PubMed PubMed Citation Articles by Moens, A. L. Articles by Kass, D. A.

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2006;26:2439.)
© 2006 American Heart Association, Inc.

Brief Reviews

Tetrahydrobiopterin and Cardiovascular Disease

An L. Moens; David A. Kass

From the Division of Cardiology, Department of Medicine, Johns Hopkins Medical Institutions, Baltimore, Md.

Correspondence to David A. Kass, MD, Ross 835, Division of Cardiology, Johns Hopkins Medical Institutions, 720 Rutland Avenue, Baltimore, MD 21205. E-mail dkass{at}jhmi.edu

Tetrahydrobiopterin (BH₄) is an essential cofactor for the aromatic amino acid hydroxylases, which are essential in the formation of neurotransmitters, and for nitric oxide synthase. It is presently used clinically to treat some forms of phenylketonuria (PKU) that can be ameliorated by BH₄ supplementation. Recent evidence supports potential cardiovascular benefits from BH₄ replacement for the treatment of hypertension, ischemia-reperfusion injury, and cardiac hypertrophy with chamber remodeling. Such disorders exhibit BH₄ depletion because of its oxidation and/or reduced synthesis, which can result in functional uncoupling of nitric oxide synthase (NOS). Uncoupled NOS generates more oxygen free radicals and less nitric oxide, shifting the nitroso-redox balance and having adverse consequences on the cardiovascular system. While previously difficult to use as a treatment because of chemical instability and cost, newer methods to synthesize stable BH4 suggest its novel potential as a therapeutic agent. This review discusses the biochemistry, physiology, and evolving therapeutic potential of BH4 for cardiovascular disease.

Tetrahydrobiopterin (BH₄) is an essential cofactor for the aromatic amino acid hydroxylases, which are essential in the formation of neurotransmitters, and for nitric oxide synthase (NOS). BH₄ replacement may help treat hypertension, ischemia-reperfusion injury, and cardiac hypertrophy with chamber remodeling, by restoring functional NOS. This review discusses BH₄ biochemistry, physiology, and evolving uses to treat cardiovascular disease.

Key Words: tetrahydrobiopterin • nitric oxide synthase • atherosclerosis • inflammation

This article has been cited by other articles:

				S. Wang, J. Xu, P. Song, Y. Wu, J. Zhang, H. Chul Choi, and M.-H. Zou Acute Inhibition of Guanosine Triphosphate Cyclohydrolase 1 Uncouples Endothelial Nitric Oxide Synthase and Elevates Blood Pressure Hypertension, September 1, 2008; 52(3): 484 - 490. [Abstract] [Full Text] [PDF]

				C. G. Tankersley, H. C. Champion, E. Takimoto, K. Gabrielson, D. Bedja, V. Misra, H. El-Haddad, R. Rabold, and W. Mitzner Exposure to inhaled particulate matter impairs cardiac function in senescent mice Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2008; 295(1): R252 - R263. [Abstract] [Full Text] [PDF]

				N. Sasaki, T. Yamashita, T. Takaya, M. Shinohara, R. Shiraki, M. Takeda, N. Emoto, A. Fukatsu, T. Hayashi, K. Ikemoto, et al. Augmentation of Vascular Remodeling by Uncoupled Endothelial Nitric Oxide Synthase in a Mouse Model of Diabetes Mellitus Arterioscler. Thromb. Vasc. Biol., June 1, 2008; 28(6): 1068 - 1076. [Abstract] [Full Text] [PDF]

				A. L. Moens, E. Takimoto, C. G. Tocchetti, K. Chakir, D. Bedja, G. Cormaci, E. A. Ketner, M. Majmudar, K. Gabrielson, M. K. Halushka, et al. Reversal of Cardiac Hypertrophy and Fibrosis From Pressure Overload by Tetrahydrobiopterin: Efficacy of Recoupling Nitric Oxide Synthase as a Therapeutic Strategy Circulation, May 20, 2008; 117(20): 2626 - 2636. [Abstract] [Full Text] [PDF]

				J. A. Hill and E. N. Olson Cardiac Plasticity N. Engl. J. Med., March 27, 2008; 358(13): 1370 - 1380. [Full Text] [PDF]

				E. Yamamoto, K. Kataoka, H. Shintaku, T. Yamashita, Y. Tokutomi, Y.-F. Dong, S. Matsuba, H. Ichijo, H. Ogawa, and S. Kim-Mitsuyama Novel Mechanism and Role of Angiotensin II Induced Vascular Endothelial Injury in Hypertensive Diastolic Heart Failure Arterioscler. Thromb. Vasc. Biol., December 1, 2007; 27(12): 2569 - 2575. [Abstract] [Full Text] [PDF]

				J. Xu, Y. Wu, P. Song, M. Zhang, S. Wang, and M.-H. Zou Proteasome-Dependent Degradation of Guanosine 5'-Triphosphate Cyclohydrolase I Causes Tetrahydrobiopterin Deficiency in Diabetes Mellitus Circulation, August 21, 2007; 116(8): 944 - 953. [Abstract] [Full Text] [PDF]